Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Analysts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given a consensus rating of “Hold” by the five analysts that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $3.33.

Separately, Wall Street Zen started coverage on shares of Syros Pharmaceuticals in a report on Friday, May 16th. They issued a “sell” rating on the stock.

Syros Pharmaceuticals Stock Performance

Shares of NASDAQ SYRS opened at $0.03 on Friday. The business’s 50-day simple moving average is $0.03 and its 200-day simple moving average is $0.13. Syros Pharmaceuticals has a 52 week low of $0.02 and a 52 week high of $6.93. The firm has a market cap of $694,948.80, a price-to-earnings ratio of -0.01 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. Two Sigma Securities LLC acquired a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned approximately 0.40% of Syros Pharmaceuticals at the end of the most recent quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.